The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori

Hepato-Gastroenterology

Volumn 57, Issue 102-103, 2010, Pages 1314-1319

  Furuta, Takahisa ^a   Sugimoto, Mitsushige ^a   Kodaira, Chise ^a   Nishino, Masafumi ^a   Yamade, Mihoko ^a   Uotani, Takahiro ^a   Ikuma, Mutsuhiro ^a   Shirai, Naohito ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JA Shizuoka Kohseiren Enshu Hospital   (Japan)

Author keywords

Amoxicillin; CYP2C19; H. Pylori; Rabeprazole; Rescue

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; METRONIDAZOLE; MIYA BM; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; SITAFLOXACIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DUODENUM ULCER; ENDOSCOPY; ERADICATION THERAPY; FEMALE; GASTRITIS; GENETIC ASSOCIATION; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; LOOSE FECES; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; STOMACH ULCER; THRUSH; TREATMENT RESPONSE; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AMOXICILLIN; ARYL HYDROCARBON HYDROXYLASES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED;

EID: 79251572641     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Blaser MJ: Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102(2):720-727.
2. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Phillips M, Waters TE, Sanderson CR: Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988; 2(8626-8627):1437-42.
3. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH: Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997; 126(4):280-291.
4. Furuta T, Futami H, Arai H, Hanai H, Kaneko E: Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. J Clin Gastroenterol 1995; 20(Suppl 2):S107-S111.
5. Wotherspoon AC: Helicobacter pylori infection and gastric lymphoma. Br Med Bull 1998; 54(1):79-85. (Pubitemid 28105317)
6. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G: Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6(8):639-642.
7. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345(11):784-789.
8. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372(9636):392-397.
9. Walsh JH, Peterson WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333(15):984-991.
10. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J: Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003; 17(1):119-123
11. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T: Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5(2):181-202
12. Sohn DR, Kwon JT, Kim HK, Ishizaki T: Metabolic disposition of lansoprazole in relation to the S-mepheny- toin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 61 1997; (5):574-582.
13. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 57 1995; (6):662-669.
14. Andersson T:Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31(1):9-28.
15. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65(5):552-561. (Pubitemid 29237329)
16. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15(12):1929-1937.
17. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14(10):1259-1266.
18. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129(12):1027-1030.
19. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, Sugimura H, Ohashi K, Ishizaki T: Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001 11(4):341-348.
20. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69(3):158-168. (Pubitemid 32225416)
21. Aoyama N, Tanigawara Y, Kita T, Sakai T, Shirakawa K, Shirasaka D, Kodama F, Okumura K, Kasuga M: Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 1999;34(Suppl 11):80-83.
22. Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, Okumura K: CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999; 66(5):528-534.
23. Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T: High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003; 50(54):2274-2278.
24. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′- hydroxylation status. Clin Pharmacol Ther 1995; 58(2):143-154.
25. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K: CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18 (6):721-727.
26. Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24- h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12(11):1079-1089.
27. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16(10):1811-1817.
28. Dent JC, McNulty CA: Evaluation of a new selective medium for Campylobacter pylori. Eur J Clin Microbiol Infect Dis 1988; 7(4):555-558.
29. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 1998; 93(3):386-389.
30. Furuta T, Soya Y, Sugimoto M, Shirai N, Nakamura A, Kodaira C, Nishino M, Okuda M, Okimoto T, Murakami K, Fujioka T, Hishida A: Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J Gastroenterol Hepatol 2007; 22(11):1810-1815.
31. Kato M, Asaka M, Ohara S, Toyota T: Clinical studies of 13C-urea breath test in Japan. J Gastroenterol 1998; 33 Suppl 10: 36-39. (Pubitemid 29008444)
32. Furuta T, Baba S, Takashima M, Futami H, Arai H, Kajimura M, Hanai H, Kaneko E: Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol 1998; 33(4):357-363.
33. Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, Yoneyama M, Ohashi K, Ishizaki T, Hishida A: Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori Infection. Clin Gastroenterol Hepatol 2005; 3(6):564-573.
34. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79(1):103-113.
35. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989: 8(10):888-889.
36. Scott D, Weeks D, Melchers K, Sachs G: The life and death of Helicobacter pylori. Gut 1998; 43 Suppl 1: S56-S60.
37. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, Spiller RC: Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111(2):358-367.
38. Midolo PD, Turnidge JD, Lambert JR, Bell JM: Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob Agents Chemother 1996; 40(6):1531-1533.
39. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38(4):402-408.
40. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ: Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′- hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9(5):539-549.
41. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60(6):661-666.
42. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M, Kosuge K, Hanai H, Chiba K, Ishizaki T, Kaneko E: Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999; 66(3):265-274.
43. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, Heldwein W, Klann H, Simon T, Schmitt W, et al: Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108(5):1412-1417.
44. Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bastlein E, Papke J, Jacobs E, Vieth M, Stolte M, Lehn N, Bayerdorffer E: A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8(4):310-319.
45. Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T: Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther 2000; 67(6):684-689. (Pubitemid 30416085)
46. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T: Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70(5):484-492.
47. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T: Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76(4):290-301.
48. Shirai N, Sugimoto M, Kodaira C, Nishino M, Ikuma M, Kajimura M, Ohashi K, Ishizaki T, Hishida A, Furuta T: Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007; 63(8):743-749.
49. Tsuchiya M, Imamura L, Park JB, Kobashi K: Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995; 18(8):1053-1056.
50. Kawakami Y, Akahane T, Yamaguchi M, Oana K, Takahashi Y, Okimura Y, Okabe T, Gotoh A, Katsuyama T: In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44(2):458-461.
51. Athamna A, Athamna M, Medlej B, Bast DJ, Rubinstein E: In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J Antimicrob Chemother 2004; 53(4):609-615.